Back

Curocell’s Limkato clears reimbursement review for Korea’s first CAR-T therapy

Verifying
  • Curocell’s Limkato cleared reimbursement review for national insurance coverage in South Korea.
  • Limkato recorded a 75.3% objective response rate in its Phase 2 trial.
  • Limkato received drug approval in April and passed cancer review in July.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Curocell’s Limkato clears reimbursement review for Korea’s first CAR-T therapy - CoinPost Terminal